Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2008-02-22
2010-10-19
Chernyshev, Olga N (Department: 1649)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S002600, C424S278100, C424S279100, C424S184100, C424S185100, C424S192100
Reexamination Certificate
active
07816322
ABSTRACT:
The invention provides compositions and methods for treating, preventing, and diagnosing diseases or conditions associated with an abnormal level or activity of biglycan; disorders associated with an unstable cytoplasmic membrane, due, e.g., to an unstable dystrophin associated protein complex (DAPC); disorders associated with abnormal synapses or neuromuscular junctions, including those resulting from an abnormal MuSK activation or acetylcholine receptor (AChR) aggregation. Examples of diseases include muscular dystrophies, such as Duchenne's Muscular Dystrophy, Becker's Muscular Dystrophy, neuromuscular disorders and neurological disorders.
REFERENCES:
patent: 5340934 (1994-08-01), Termine et al.
patent: 5654270 (1997-08-01), Ruoslahti
patent: 5705609 (1998-01-01), Ruoslahti et al.
patent: 6864236 (2005-03-01), Fallon et al.
patent: 2004/0063627 (2004-04-01), Fallon et al.
patent: 2005/0059580 (2005-03-01), Fallon et al.
patent: 0 686 397 (1995-04-01), None
patent: WO-93/10808 (1993-06-01), None
patent: WO-95/13298 (1995-05-01), None
patent: WO-01/36475 (2001-05-01), None
patent: WO-03/015615 (2003-02-01), None
patent: WO-03/070195 (2003-08-01), None
Bianco, P., et al., “Expression and Localization of the Two Small Proteoglycans Biglycan and Decorin in Developing Human Skeletal and Non-skeletal Tissues,”J. Histochem. Cytochem., 38(11):1549-1563 (1990).
Bowe, M.A., et al., “The Small Leucine-rich Repeat Proteoglycan Biglycan Binds to Dystroglycan and Is Upregulated in Dystrophic Muscle,”J. Cell Biol.148(4):801-810 (2000).
Chan, Y., et al., “Molecular Organization of Sarcoglycan Complex in Mouse Myotubes in Culture,”J. Cell Bio., 143(7):2033-2044 (1998).
Coral-Vazquez, R., et al., “Disruption of the Sarcoglycan-Sarcospan Complex in Vascular Smooth Muscle: A Novel Mechanism for Cardiomyopathy and Muscular Dystrophy,”Cell, 98:465-474 (1999).
Crosbie, R., et al., “Membrane Targeting and Stabilization of Sarcospan is Mediated by the Sarcoglycan Subcomplex,”J. Cell Bio., 145(1):153-165 (1999).
Ervasti, J.M. and Campbell, K.P., “A Role for the Dystrophin-Glycoprotein Complex as a Transmembrane Linker between Laminin and Actin,”J. Cell Bio., 122(4):809-823 (1993).
Ferri, R.T., et al., “A role for biglycan in agrin-induced postsynaptic differentiation,”Society for Neuroscience Abstracts, 26 (2000) (Abstract only).
Fisher, L.W., et al.,“Deduced Protein Sequence of Bone Small Proteoglycan I (Biglycan) Shows Homology with Proteoglycan II (Decorin) and Several Nonconnective Tissue Proteins in a Variety of Species,”J. Bio. Chem., 264(8):4571-4576 (1989).
Gee, S.H., et al., “Dystroglycan-α, a Dystrophin-Associated Glycoprotein, Is a Functional Agrin Receptor,”Cell, 77:675-686 (1994).
Guglieri, et al., “Molecular Etiopathogenesis of Limb Girdle Muscular and Congenital Muscular Dystrophies: Boundaries and Contiguities,” Clinica Chimica Acta 361 (2005) 54-79.
Hasenohrl et al. 1995, Behav. Brain Res. 70, 59-67.
Hoch, W., “Formation of the neuromuscular junction: Agrin and its unusual receptors,”Eur. J. Biochem., 265:1-10 (1999).
Hocking, A.M., et al., “Eukaryotic Expression of Recombinant Biglycan,”Am. Soc. for Biochem. and Molecular Biol., 271(32):19571-19577 (1996).
Holt, K.H., et al., “Functional Rescue of the Sarcoglycan Complex in the BIO 14.6 Hamster Using δ-Sarcoglycan Gene Transfer,”Molecular Cell, 1:841-848 (1998).
Ibraghimov-Beskrovnaya, O., et al., “Human dystroglycan: skeletal muscle cDNA, genomic structure, origin of tissue specific isoforms and chromosomal localization,”Hum. Mol. Genet., 2(10):1651-1657 (1993).
Iozzo, R.V., “Matrix Proteoglycans: From Molecular Design to Cellular Function,”Annu. Rev. Biochem., 67:609-52 (1998).
Jarvelainen, H.T., et al., “Differential Expression of Small Chondroitin/Dermatan Sulfate Proteoglycans, PG-I/Biglycan and PG-II/Decorin, by Vascular Smooth Muscle and Endothelial Cells in Culture,”J. Biol. Chem., 266:23274-23281 (1991).
Junghans, U., et al., “Purification of a Meningeal Cell-derived Chondroitin Sulphate Proteoglycan with Neurotrophic Activity for Brain Neurons and its Identification as Biglycan,”Eur. J. Neuroscience, 7:2341-2350 (1995).
Khurana, T.S., et al., “Interaction of Aria, A Neuregulin, with the Dystroglycan / Sarcoglycan Complex in Skeletal Muscle,” Mol. Cell Biol., 7, 314, 631-6, 1996.
Krishnan, P., et al., “Distinct Secondary Structures of the Leucine-rich Repeat Proteoglycans Decorin and Biglycan,”J. Biol. Chem., 274(16):10945-10950 (1999).
Lampe et al., “Collagen VI Related Muscle Disorders,” J. Med. Genet. 2005;42;673-685.
Raffi et al., “Interactions of the Proteoglycan Biglycan with the Dystrophin Associated Protein Complex and its Roles in Muscular Dystrophy and Synaptogenesis,”Molecular Biology of the Cellvol. 11 pp. 146a (2000).
Sakamoto, A., et al., “Both hypertrophic and dilated cardiomyopathies are caused by mutation of the same gene, δ-sarcoglycan, in hamster: An animal model of disrupted dystrophin-associated glycoprotein complex,”Proc. Natl. Acad. Sci. USA, 94:13873-13878 (1997).
Speer et al., “Evidence for locus heterogeneity in the Bethlem myopathy and linkage to 2q37,” Hum. Mol. Genet. Jul. 1996;5(7):1043-6.
Spence et al., “Muscular dystrophies, the cytoskeleton and cell adhesion,” BioEssays 24:542-552, 2002.
Tomoyasu, H., et al., “Identification of haemopoietic biglycan in hyperplastic thymus associated with myasthenia gravis,”J Neuroimmunology, 89:59-63 1998.
Vanegas et al., “Ullrich scleroatonic muscular dystrophy is caused by recessive mutations in collagen type VI,” PNAS vol. 98, No. 13, 2001.
Von der Mark et al., “Immunochemistry, genuine size and tissue localization of collagen VI,” Eur. J. Biochem. 142(3):493-502, 1984.
Wiberg et al., “Biglycan and Decorin Bind Close to the N-terminal Region of the Collagen VI Triple Helix,” J. Biol. Chem., 276;22, 18947-18952, 2001.
Winder, S.J., “The complexities of dystroglycan,”Trends in Biochem. Sci., 26:118-124 (2001).
Peat et al., Exclusion of biglycan mutations in a cohort of patients with neuromuscular disorders. Neuromuscul Disord. Aug. 2008;18(8):606-9. Epub Jul. 7, 2008.
Mercado et al., Biglycan regulates the expression and sarcolemmal localization of dystrobrevin, syntrophin, and nNOS. FASEB J. Aug. 2006;20(10):1724-6. Epub Jun. 28, 2006.
Amenta Alison
Bowe Mark A.
Fallon Justin R.
Hagiwara Hiroki
McKechnie Beth
Brown University Research Foundation
Chernyshev Olga N
Ropes & Gray LLP
LandOfFree
Biglycan and related therapeutics and methods of use does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Biglycan and related therapeutics and methods of use, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Biglycan and related therapeutics and methods of use will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4207028